Regencell Bioscience Holdings Limited RGC
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.32M | -3.59M | -1.85M | -1.85M | -1.85M |
| Total Depreciation and Amortization | 40.80K | 46.30K | 51.80K | 51.80K | 51.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.69M | 1.39M | 98.00K | 98.00K | 98.00K |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | -2.59M | -2.15M | -1.70M | -1.70M | -1.70M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.50M | 1.38M | 255.60K | 255.60K | 255.60K |
| Cash from Investing | 2.50M | 1.38M | 255.60K | 255.60K | 255.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 25.60K | 44.50K | 63.40K | 63.40K | 63.40K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -62.00K | -723.50K | -1.39M | -1.39M | -1.39M |